Cancer discovery news
Our researchers are making the discoveries that defeat cancer. Read the latest findings from our world-leading research.
Visit our main news hub to read about news on new funding, our fundraising activities and much more. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Shorter radiotherapy courses for prostate cancer are well tolerated long-term by patients
A shorter course of radiotherapy, administered through fewer, higher intensity doses, is as well tolerated over five years as longer treatment courses for treating prostate cancer, long-term results of a clinical trial show.
Monte Rosa Therapeutics lists on New York Stock Exchange
Monte Rosa Therapeutics, a biotechnology company originally formed as a spinout from science at The Institute of Cancer Research, London, partly funded by Cancer Research UK, is now listed on the Nasdaq stock exchange in New York.
Cancer vaccine could be effective way to overcome treatment resistance
A cancer vaccine could be an effective way to prevent cancer from evolving and becoming resistant to treatment, new research suggests.
ICR comes top in university invention income for eighth successive year
The Institute of Cancer Research, London, has earned the most staff-adjusted invention income of any UK higher education institution for the eighth year in a row.
Shorter course of radiotherapy safely delivers treatment for prostate cancer
Advanced radiotherapy technology can safely deliver curative treatment for prostate cancer patients in as few as five sessions, with only minimal side effects, according to new research from The Royal Marsden NHS Foundation Trust and the ICR.
A visionary research leader, ally and mentor - Professor Paul Workman steps down as CEO
As Professor Paul Workman steps down as Chief Executive of The Institute of Cancer Research, London, colleagues from the ICR and beyond share memories of and reflections on his impact in cancer research.
-547x410.jpg?sfvrsn=5e98f2c_2 "Clinical trials pharmacy (Jan Chlebik for the ICR, 2014) 547x410")
Innovative ICR-discovered drug to enter first clinical trial, targeting HSF1 pathway
Cancer patients are set to receive, for the first time, a highly innovative investigational drug called NXP800 – which was discovered at The Institute of Cancer Research, London.
Celebrating the ICR’s achievements under Professor Paul Workman’s leadership
Professor Paul Workman steps down as Chief Executive of The Institute of Cancer Research. Here, we look back at a selection of the many ICR achievements during his leadership.
New BRCA-targeting drug could offer hope in treating advanced prostate cancer
Talazoparib, a new precision drug, can keep cancer in check in some men with advanced prostate cancer who have run out of options, a phase II clinical trial shows.
Recreating a signalling process in the test tube provides clues to bowel cancer
Scientists have, for the first time, recreated an assembly of proteins known as the β-catenin destruction complex in the test tube. This is a long-awaited step in cancer research, as mutations in this destruction complex are found in a large percentage of bowel and other cancers.
Combination drug therapy can significantly benefit patients with newly diagnosed blood cancer
A four-drug combination therapy that includes the novel drug carfilzomib can slow the progression of the blood cancer myeloma in patients who have been newly diagnosed with the disease, a phase III study has shown.
Scoring system predicts head and neck cancer patient response to immunotherapy
A prognostic scoring system that is cheap, efficient and reliable can predict how patients with relapsed and/or metastatic head and neck cancer will respond to immunotherapy, new research has shown.